B: Overall survival (OS) of individuals assigned to Cohort 1 or Cohort 2. pre-antibody-positive individuals. No tumor shrinkage was observed. The individuals who received 200?g of CHP-NY-ESO-1 survived longer than individuals receiving 100?g of CHP-NY-ESO-1, even those who exhibited unresponsiveness to previous therapies or had higher tumor burdens. Conclusions The security and immunogenicity of CHP-NY-ESO-1 vaccine were confirmed. The 200?g dose more efficiently induced immune responses and suggested better survival benefits. (Clinical trial sign up quantity NCT01003808). Keywords: Esophageal malignancy, Tumor vaccine, NY-ESO-1, Cholesteryl pullulan (CHP) Background Complexes of cholesteryl pullulan (CHP) nano-particles that contain a tumor antigen are a fresh type of malignancy vaccine having a novel antigen delivery system that presents multiple epitope peptides to both the MHC class I and class II pathways [1-4]. We have been developing CHP-protein human being tumor vaccines that efficiently induce immune RAF mutant-IN-1 reactions against multiple T cell epitopes for numerous HLA types. Earlier medical studies using CHP-HER2 and RAF mutant-IN-1 CHP-NY-ESO-1 vaccines showed that these vaccines could be given repeatedly without severe adverse effects, and RAF mutant-IN-1 both vaccines induced antigen-specific CD4+ and CD8+ T cell immunity as well as humoral immunity [5-7]. Because the NY-ESO-1 antigen is definitely a cancer-testis antigen that is specifically indicated in the tumor cells, aside from manifestation in the normal testis and placenta, this antigen is considered an ideal target for malignancy immunotherapy [8,9]. The appropriate dose for NY-ESO-1 protein vaccine has not been RAF mutant-IN-1 determined, although doses up to 100?g have been examined, in which a higher dose was more immunogenic compared to lower doses of 10?g and 30?g [10]. We carried out a dose-escalating trial with CHP-NY-ESO-1 vaccine doses of 100?g and 200?g for esophageal malignancy patients who have been resistant to standard therapies. We evaluated the security and immune reactions to the NY-ESO-1 antigen on the vaccination period, and explored the medical impact on esophageal malignancy patients with a poor prognosis. In this study, we analyzed IgG antibody reactions as antigen-specific immune reactions. Although T cells that are induced by Rabbit Polyclonal to EDG2 a malignancy vaccine should be evaluated as an immune-monitoring marker, T cells can be hard to detect directly and quantitatively assess, whereas IgG titers measured by ELISA could act as a suitable immune-monitoring marker. Analyzing antibody reactions induced by CHP-NY-ESO-1 vaccine, the 200?g-dose more efficiently induced immune reactions and suggested better survival benefits. Materials and methods Preparation of CHP-NY-ESO-1 complex vaccine CHP-NY-ESO-1 complex vaccine (Drug code: IMF-001) was provided by ImmunoFrontier, Inc. (Tokyo, Japan). All processes were performed following current Good Manufacturing Methods (cGMP) conditions. The toxicity of the drug products was assessed using animal models, and stability was monitored during the medical trial using representative samples of the investigational drug product. Study design This study was a phase 1, open-label, multi-institutional, dose-escalating medical trial of the CHP-NY-ESO-1 complex RAF mutant-IN-1 vaccine given subcutaneously to individuals with unresectable, advanced, or refractory esophageal tumors that indicated the NY-ESO-1 antigen. The primary objective was to determine the maximum tolerated dose (MTD) and the biological recommended dose, and the secondary objective was to assess medical efficacy. Patients were eligible for access, if they experienced a overall performance status of 0, 1, or 2, were at least 20?years old, had a life expectancy of 4?months or more, and did not have impaired organ function. Patients were ineligible if they were positive for HIV antibody, experienced multiple cancers, autoimmune disease, severe allergy history, or active mind metastasis, or received earlier chemotherapy, systemic steroid or immunosuppressive therapy within less than 4?weeks. The.